Clinical Trial Search

Primary: Progression-Free Survival (PFS) in Patients With Non-germinal Center B-cell-like (Non-GCB) Diffuse Large B-cell Lymphoma (DLBCL) — NA; NA months

Primary: Overall Response Rate (ORR) As Measured By The Investigator — 35; 56.3; 60.0 Percentage of Participants

Primary: Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population — 49.64; 54.77 Months — p=0.5167

Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…

Primary: Complete Response (CR) Rate — 64.5; 63.5 percentage of participants — p=0.915

Primary: Number of Participants With Adverse Events (e.g. Toxicity) — 28 Participants

Primary: Overall Response Rate — 38 percentage of participants

Primary: Percentage of Patients With an Overall Response to Study Drug — 24.3; 12.5 percentage of participants

Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg

Primary: Objective Response Rate — 3 Participants

Primary: Overall Response (OR) Rate — 36 Participants

Primary: Percentage of Participants With Dose-Limiting Toxicities (DLTs) — 0.0; 50.0; 0.0; 0.0 percentage of participants

Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519

Primary: Mean Change From Baseline to Month 9 in Hemoglobin (Hgb) Concentration for Each Treatment Group. — 1.624; 1.488 gram per deciliter (g/dl)

Primary: Change From Baseline to 12 Months in Hemoglobin Concentration for the 60 U/kg Treatment Group. — 2.429 g/dL — p=<0.0001